120O Pembrolizumab (Pembro) with or without lenvatinib (Lenva) in first-line metastatic NSCLC with PD-L1 TPS ≥1% (LEAP-007): A phase III, randomized, double-blind study
James Chih‐Hsin Yang(National Taiwan University Hospital), Tibor Csőszi, Naveen S. Basappa, Xavier Quantin(Inserm), Emmanuel de la Mora Jimenez(Instituto Jalisciense de Cancerología), Lorenzo Livi(European Society for Sexual Medicine), Ayman Samkari(Merck & Co., Inc., Rahway, NJ, USA (United States)), Nuri Karadurmuş(Sağlık Bilimleri Üniversitesi), Alexander Luft(Leningrad Regional Cancer Center), P. Koralewski(Unknown), Zachary Zimmer(Merck & Co., Inc., Rahway, NJ, USA (United States)), Shunichi Sugawara(Sendai Kousei Hospital), Julia Dudnik(Soroka Medical Center), Niyati Bhagwati(Merck & Co., Inc., Rahway, NJ, USA (United States)), Tarek Mekhail(AdventHealth Orlando), Chinyere E. Okpara(Eisai (United Kingdom)), Daisy Ortiz, Jun S. Lee(Seoul National University)
Cited by 20
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k